Pharmacloud was established in 2009 by Frances Cloud, who was previously an equity analyst and M&A adviser covering the European generic sector. Pharmacloud’s original focus was on writing research about the generic pharmaceutical industry, but since then it has expanded its activities to encompass commercial due diligence, market mapping, market entry strategies, strategic consultancy and M&A support. Europe remains the primary focus, but Pharmacloud has recently completed a number of projects in the US and is increasingly operating in MENA and other emerging markets. Pharmacloud has been involved in many if not most of the generic M&A transactions that have taken place in Europe over the last five years, mainly assisting PE, and is very active in identifying and diligencing big pharma tail end assets for a variety of trade and financial clients.
At present, the research side of the business consists of an ad-hoc blog covering sector news of interest. If you want to receive this, click here to sign up. During 2015, we expect to start publishing some longer reports covering specific industry topics, so watch out for these appearing on our website.
If you would like to get in touch to discuss a particular project, please contact us by calling Frances Cloud on +44 7802 925 797 or by emailing
